EUVIMEDEUVIMED entdecken
Crossref

Mulberry Leaf Lipid Nanoparticles: a Naturally Targeted CRISPR/Cas9 Oral Delivery Platform for Alleviation of Colon Diseases

Lingli Ma, Ya Ma, Qiang Gao, Shengsheng Liu, Zhenhua Zhu, Xiaoxiao Shi, Fangyin Dai, Rui L Reis, Subhas C Kundu, Kaiyong Cai, Bo Xiao iD

Small · 2024-06 · 20 (25)

DOI: 10.1002/smll.202307247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 20.01.2024. Verfasst von Lingli Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Resource Insects, College of Sericulture, Textile, and Biomass Sciences, Southwest University, Chongqing, 400715, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Nanoparticles, Plant Leaves, Morus. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Jiangxi Province, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral treatment of colon diseases with the CRISPR/Cas9 system has been hampered by the lack of a safe and efficient delivery platform. Overexpressed CD98 plays a crucial role in the progression of ulcerative colitis (UC) and colitis‐associated colorectal cancer (CAC). In this study, lipid nanoparticles (LNPs) derived from mulberry leaves are functionalized with Pluronic copolymers and optimized to deliver the CRISPR/Cas gene editing machinery for CD98 knockdown. The obtained LNPs possessed a hydrodynamic diameter of 267.2 nm, a narrow size distribution, and a negative surface charge (−25.6 mV). Incorporating Pluronic F127 into LNPs improved their stability in the gastrointestinal tract and facilitated their penetration through the colonic mucus barrier. The galactose end groups promoted endocytosis of the LNPs by macrophages via asialoglycoprotein receptor‐mediated endocytosis, with a transfection efficiency of 2.2‐fold higher than Lipofectamine 6000. The LNPs significantly decreased CD98 expression, down‐regulated pro‐inflammatory cytokines (TNF‐ α and IL‐6), up‐regulated anti‐inflammatory factors (IL‐10), and polarized macrophages to M2 phenotype. Oral administration of LNPs mitigated UC and CAC by alleviating inflammation, restoring the colonic barrier, and modulating intestinal microbiota. As the first oral CRISPR/Cas9 delivery LNP, this system offers a precise and efficient platform for the oral treatment of colon diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNanoparticlesPlant LeavesMorusLipidsAnimalsAdministration, OralMiceColonic DiseasesHumansMaleLiposomes

Stichwörter der Autor:innen

CRISPR/Cas9colon diseasemacrophage‐targetingoral administrationplant lipid nanoparticles

Substanzen

LipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • State Key Laboratory of Resource Insects, College of Sericulture, Textile, and Biomass Sciences, Southwest University, Chongqing, 400715, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
  • Bs Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, University of Minho, Av…
  • ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, 4800-058, Portugal.
  • Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China.

ORCID-Profile: Bo Xiao

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Jiangxi Province
  • Fundamental Research Funds for the Central Universities
  • Venture & Innovation Support Program for Chongqing Overseas Returnees
  • Science Fund for Distinguished Young Scholars of Chongqing Municipality

Zitieren

APA

Ma, L., Ma, Y., Gao, Q., Liu, S., Zhu, Z., Shi, X., Dai, F., Reis, R. L., Kundu, S. C., Cai, K., & Xiao, B. (2024). Mulberry Leaf Lipid Nanoparticles: a Naturally Targeted CRISPR/Cas9 Oral Delivery Platform for Alleviation of Colon Diseases. Small, 20(25). https://doi.org/10.1002/smll.202307247

Vancouver

Ma L, Ma Y, Gao Q, Liu S, Zhu Z, Shi X, et al. Mulberry Leaf Lipid Nanoparticles: a Naturally Targeted CRISPR/Cas9 Oral Delivery Platform for Alleviation of Colon Diseases. Small. 2024;20(25). doi:10.1002/smll.202307247

BibTeX
@article{Ma2024,
  author = {Ma, Lingli and Ma, Ya and Gao, Qiang and Liu, Shengsheng and Zhu, Zhenhua and Shi, Xiaoxiao and Dai, Fangyin and Reis, Rui L and Kundu, Subhas C and Cai, Kaiyong and Xiao, Bo},
  title = {Mulberry Leaf Lipid Nanoparticles: a Naturally Targeted CRISPR/Cas9 Oral Delivery Platform for Alleviation of Colon Diseases},
  journal = {Small},
  year = {2024},
  volume = {20},
  number = {25},
  doi = {10.1002/smll.202307247}
}
Kostenlos starten →